SCHEMBL16635592

SCHEMBL16635592

COC(=O)[C@@H]1CCCC[C@H]1c1nc(-c2ccc(F)cc2)sc1-c1ccc(C2CN(C(=O)O)C2)cc1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CTSK P43235 1/20 0.45
SLC6A2 P23975 4/20 0.44
SLC6A4 P31645 3/20 0.44
PDE9A O76083 1/20 0.36
HCRTR1 O43613 2/20 0.34
HCRTR2 O43614 2/20 0.34
PPARD Q03181 1/20 0.34
PPARA Q07869 1/20 0.34
ALOX5 P09917 1/20 0.34
PAX8 Q06710 1/20 0.34
ACHE P22303 1/20 0.34
SLC6A3 Q01959 3/20 0.33
NPC1 O15118 1/20 0.33
MAPT P10636 1/20 0.33
RAB9A P51151 1/20 0.33
CHRM4 P08173 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18010300 0.89 PDE4B (0.43) CTSKSLC6A2SLC6A4
SCHEMBL16635842 0.89 PDE4B (0.43) CTSKSLC6A2SLC6A4PDE9ASLC6A3
SCHEMBL16635986 0.87 CTSK (0.42) CTSKSLC6A2SLC6A4PDE9AHCRTR1
SCHEMBL16635840 0.85 SLC6A2 (0.43) CTSKSLC6A2SLC6A4PDE9AHCRTR1
Trifluoroacetic Acid SCHEMBL16635984 0.84 SLC6A2 (0.42) CTSKSLC6A2SLC6A4PDE9AHCRTR1
SCHEMBL16635811 0.82 CTSK (0.42) CTSKHCRTR1HCRTR2PPARDPPARA
SCHEMBL18279802 0.79 CTSK (0.48) CTSKSLC6A2SLC6A4PDE9A
SCHEMBL16636408 0.79 SLC6A2 (0.45) CTSKSLC6A2SLC6A4NPC1RAB9A
SCHEMBL16636407 0.79 SLC6A2 (0.45) CTSKSLC6A2SLC6A4NPC1RAB9A
SCHEMBL16636395 0.76 CTSK (0.68) CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ CTSK 4/4885SLC6A2 4308/4885SLC6A4 4386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.